论文信息 - ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer - 字舞流文

ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer

S. Lheureux | P. Zola | J. Sehouli | P. Pautier | D. Cibula | R. Arend | B. Kim | S. Keefe | D. O’Malley | R. Mądry | K. Fujiwara | V. Salutari | S. Topuz | M. Puglisi | J. Korach | Q. Liu | C. Lai | I. Vergote | B. Monk | R. Coleman | K. Hasegawa | A. Gonzalez-Martinez